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Abstract Intestinal macrophages, preferentially located in
the subepithelial lamina propria, represent the largest pool
of tissue macrophages in humans. As an adaptation to the
local antigen- and bacteria-rich environment, intestinal
macrophages exhibit several distinct phenotypic and func-
tional characteristics. Notably, microbe-associated molecu-
lar pattern receptors, including the lipopolysaccharide
(LPS) receptors CD14 and TLR4, and also the Fc receptors
for IgA and IgG are absent on most intestinal macrophages
under homeostatic conditions. Moreover, while macro-
phages in the intestinal mucosa are refractory to the
induction of proinflammatory cytokine secretion, they still
display potent phagocytic activity. These adaptations allow
intestinal macrophages to comply with their main task, i.e.,
the efficient removal of microbes while maintaining local
tissue homeostasis. In this paper, we review recent findings
on the functional differentiation of monocyte subsets into
distinct macrophage populations and on the phenotypic and
functional adaptations that have evolved in intestinal
macrophages in response to their antigen-rich environment.
Furthermore, the involvement of intestinal macrophages in
the pathogenesis of celiac disease and inflammatory bowel
diseases is discussed.
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Differentiation of monocyte/macrophage subsets
Macrophages represent a functionally and phenotypically
highly diverse cell population which is not only crucially
involved in innate and adaptive immune reactions, but also
in embryonic development, wound repair, and maintenance
of local tissue homeostasis [1–3]. Macrophages, mono-
cytes, and their lineage-committed bone marrow (BM)
precursors constitute the mononuclear phagocyte system
(MPS), which represents a complex cellular system across
different organs.
Monocyte progenitors are continuously formed in the
BM. The myeloid differentiation process is associated with
a progressive loss of differentiation potential. Multipotent
hematopoietic precursors, such as lineage-committed pre-
cursors (Lin)−, Sca-1+, and c-kit (CD117)+ [4, 5], are
precursors for the common myeloid progenitor cells [6] and
the common lymphoid progenitor cells [7]. In CX3CR1-
EGFP transgenic mice [8], a subset of myeloid BM cells
(CD115+, CX3CR1+, CD117+, and Lin−) was identified as
precursors for macrophages and dendritic cells (DC) but not
for neutrophils [9]. These common progenitor cells of the
MPS are, therefore, called myeloid lineage macrophage-DC
progenitors (MDP). Upon adoptive transfer into the BM of
recipient mice, MDPs differentiate into circulating mono-
cytes [9, 10]. After leaving the BM, monocytes circulate in
the vasculature for several days before they enter their
target tissue to complete their differentiation into macro-
phages (Fig. 1). The selective recruitment of blood
monocyte subsets to peripheral sites of the body is crucial
for maintaining the distinct populations of differentiated
tissue macrophages [11]. Nevertheless, at least under
steady-state conditions, local cell proliferation may also
contribute to the replenishment at least of some tissue
macrophage subsets [12]. As an example, Kupffer cells
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[13], microglial cells [14], Langerhans cells [15], and
alveolar macrophages [16, 17] were shown to also
proliferate locally. In contrast to those tissue macrophages,
intestinal macrophages were reported to be nonproliferating
[18]. Remarkably, in contrast to effector cells of the
adaptive immune system, the proliferative capacity of
BM-derived macrophages is blocked after activation with
interferon-γ (IFNγ) by a cyclin-dependent kinase (Cdk)
inhibitor [19].
Research on human cells has been restricted to in vitro
studies and, thus, most data on the functional differentiation
of monocyte/macrophage subsets were obtained in animal
models. Monocyte heterogeneity is conserved between
different species, and the functional commonality of these
systems led to the identification of corresponding monocyte
subsets in human, mouse, rat, and pig [12]. Adoptive cell
transfer experiments and the availability of chemokine
receptor-deficient mouse lines were instrumental to obtain
insight into the biological heterogeneity of monocytes and
macrophages. Although the precise lineage relationships are
not yet firmly established in detail, it is generally accepted
that distinct subsets of BM and blood monocytes are the
precursors of DCs, resident macrophages (i.e., macrophages
that are located in the tissue under homeostatic conditions),
and inflammatory macrophages (also named exudate
macrophages), which are recruited to the tissues during
inflammatory conditions. In mice, the “inflammatory”
macrophages seem to be derived from a recruited, short-
lived inflammatory subset of blood monocytes. These
“inflammatory” monocytes are characterized by the high
expression of CCR2 and Ly6C and intermediate expression
of CX3CR1, while noninflammatory monocytes (CCR2−,
Ly6C−, and CX3CR1hi) may differentiate into long-lived
resident myeloid cells, including resident tissue macro-
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Fig. 1 Origin of monocytes and their differentiation into macrophages
(Mø) and dendritic cells (DC) in the intestinal lamina propria in mice.
a MDP give rise to Ly6Chigh BM monocytes [9]. b The conversion
from Ly6Chigh to Ly6Clow monocytes possibly takes place over an
intermediate cell type (Ly6Cint) in the BM [10, 38]. c BM monocytes
are released into the peripheral blood circulation, while under
homeostatic conditions (d), the majority of Ly6Chigh blood monocytes
home back to the BM [10]. e Ly6Chigh monocytes express CC-
chemokine receptor 2 (CCR2) and may be recruited to sites of
inflammation by responding to CC-chemokine ligand 2 (CCL2) [10,
20]. f Ly6Clow monocytes express CX3C-chemokine receptor 1
(CX3CR1) and possibly replenish the tissue-resident Mø and DC
populations by responding to cleaved CX3C-chemokine ligand 1
(CX3CL1). Note that CX3CL1 (fractalkine) is expressed by intestinal
epithelial and endothelial cells [101–104], while CCL2 is mainly
produced at sites of mucosal inflammation [105]. Solid arrows
represent pathways that are supported by published data, while dashed
arrows indicate proposed, still hypothetical pathways. Blue dots
proteolytically cleaved CX3CL1, red dots CCL2. BM bone marrow,
MDP Mø–DC progenitor
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phages [20]. Jung et al. have generated a reporter mouse
line in which the gene coding for the fractalkine receptor
(CX3CR1) was replaced by a green fluorescent protein
reporter gene [8]. Hence, in these CX3CR1-GFP mice, cells
of the MPS compartment can be visualized and functionally
distinct monocyte subsets can be distinguished (and
fractionated) based on the differential expression of
CX3CR1-GFP.
It is becoming increasingly evident that macrophages are
functionally highly promiscuous and that the exerted
functions are crucially determined by the local tissue
microenvironment. Hence, the broad functional diversity
of mononuclear phagocytes and the wide range of activat-
ing signals that may affect their functions is a characteristic
attribute of this cell population [12, 21, 22]. This is
reflected not only by the plasticity of the functional
phenotypes of monocyte/macrophage subsets in vitro, but
also by the diversity of functions exerted by macrophage
subsets isolated ex vivo from tissues under physiological
and inflammatory conditions. These functional and pheno-
typic adaptations are most prominent in resident macro-
phages of the intestinal mucosa and have evolved during
the coevolution of the local immune system with the
microbial flora of the gut lumen.
Heterogeneity of the mononuclear phagocyte system
Cells of the MPS show a remarkably dynamic nature of the
functions they may exert when cultured and investigated in
vitro. This is reflected in vivo by the high specialization of
tissue macrophages at different anatomical locations (e.g.,
Langerhans cells in the epidermis, osteoclasts in the bone,
microglial cells in the brain, splenic macrophages in the red
and white pulp and in the marginal zone of the spleen, and
the resident macrophages of the intestinal mucosa [12]).
The functional heterogeneity and plasticity of macrophages
is already evident in their progenitor cells, the monocytes.
In humans, monocytes are generally divided into two
distinct subsets based on their size and granularity and also
their differential expression of cell surface receptors
(pattern recognition receptors [PRRs], Fc receptors [FcRs],
and chemokine receptors). These two main monocyte
subsets may exert distinct functions and are believed to
represent precursors of distinct macrophage subsets. The
so-called inflammatory or classical monocytes are bigger
(18 µm in diameter), highly phagocytic, and represent the
larger subset (80–90% of circulating monocytes in
humans). Inflammatory monocytes are CD14hi, CCR1+,
CCR2+, CXCR2+, and CX3CR1lo and are termed “inflam-
matory” due to their inflammatory chemokine receptor
expression pattern. The so-called resident monocytes are
smaller (14 µm in diameter) and represent only 10% of the
peripheral blood monocytes. In contrast to the inflammato-
ry monocytes, resident monocytes are generally negative
for CD14 and CCR2 but express CD16, CCR5, and
CX3CR1 at high levels [23]. The classical (inflammatory)
monocytes are believed to migrate chemotactically to sites
of inflammation where the production of proinflammatory
chemokines such as MCP-1 (CCR2 ligand) and IL-
8 (CXCR2 ligand) is upregulated. Resident monocytes, on
the other hand, are recruited under homeostatic conditions
to noninflamed tissues by virtue of their pronounced
expression of CX3CR1 [24]. The classification into
inflammatory and resident populations is solely based on
the different migration behavior of these two subsets under
inflammatory and homeostatic conditions. At present, it is
not yet entirely clear to what extent this classification also
correlates with possible inflammatory vs. resident function-
al properties of the respective cell populations. As an
example, during infections, even the resident-type mono-
cyte subset (CD16+) may increase [25, 26] and these cells
produce substantial amounts of tumor necrosis factor (TNF)
upon stimulation with Toll-like receptor (TLR) agonists
[27]. Hence, macrophages with a “resident” phenotype may
also exert proinflammatory functions. Both resident and
inflammatory monocyte subsets can differentiate into DCs
in vitro by the addition of IL-4 and GM-CSF [28, 29]. An
additional, though smaller, third population of blood
monocytes was described in humans. This monocyte subset
simultaneously expresses CD14, CD16, and CD64. Be-
cause of their high phagocytic activity (shared with the
inflammatory subset) and the high expression of major
histocompatibility complex (MHC) class II (shared with the
resident subset), these cells were called transitional mono-
cytes [30, 31].
In the mouse, all circulating monocytes are CD115+,
CD11b+, and F4/80lo. Similar to their human counterparts,
murine monocytes may be further subdivided into two
major subsets, defined mainly by the differential expression
of CX3CR1, CD62L, and CCR2. Murine inflammatory
monocytes express CCR2, CD62L, and Ly6C at high levels
and express CX3CR1 at intermediate levels, while the
murine resident monocyte subset is characterized by the
high expression of CX3CR1 and the absence of CCR2 and
CD62L on the cell surface [20]. In humans as well as in the
mouse, inflammatory monocytes appear to be more
granular and, with a diameter of 10–14 µm, larger than
the resident monocytes (8–12 µm). Using Ly6C, which
shares an epitope with Gr-1, as an additional marker of the
inflammatory monocyte subset, Geissmann and collabora-
tors demonstrated that the inflammatory subset (Ly6C+)
corresponds directly to the human classical CD14+ mono-
cyte subset, thus confirming the conserved relationship of
the MPS between humans and mice. While this relevant
finding is in full support of using mouse models also for
Semin Immunopathol (2009) 31:171–184 173
defining monocyte/macrophage functions in humans, there
are still differences between the mouse and human
monocyte/macrophage system as shown in Fig. 2. The
ratio of the two main monocyte subsets is generally stable
in mice with a small excess of Ly6C+ monocytes under
homeostatic conditions [32]. Cells of the short-lived
inflammatory subset were shown to migrate to sites of
experimentally induced inflammation in a CCR2-dependent
manner. By virtue of their recognition of MCP-1 (CCL2)
and the CD62L-mediated interaction with high endothelial
venules, inflammatory monocytes are recruited to the
lymph nodes that drain the sites of inflammation [33].
The CCR2-dependent recruitment of inflammatory mono-
cytes is essential for the defense against bacterial (L.
monocytogenes) and protozoal (T. gondii) infections [34].
The exit of Ly6C+ BM monocytes from the BM may also
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Fig. 2 Frequency and phenotype of the two main circulating
monocyte subsets in humans and mice. Human inflammatory
monocytes refer to the classical CD14hiCD16− monocytes
(corresponding population in mice: CX3CR1loCCR2+), and human
resident monocytes refer to the CD14loCD16+ monocytes
(corresponding population in mice: CX3CR1highCCR2−). Expression
levels of the particular markers are semiquantitatively indicated as
minus sign absent, plus/minus sign variable, plus sign positive, double
plus sign high expression, and ND not determined. Asterisk frequen-
cies of the respective blood monocyte subsets are indicated as
percentages relative to the total circulating monocytes. Data are
derived from refs. [20, 23, 24, 31–34, 38, 106–111] and the authors’
own unpublished data. 7/4 an unidentified mouse antigen recognized
by the monoclonal antibody 7/4, F4/80 a monoclonal antibody
recognizing the mouse homolog of the human glycoprotein EMR1
(EMR1 epidermal growth factor module-containing mucin-like hor-
mone receptor 1)
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depend on CCR2-mediated chemotaxis since CCR2−/− mice
under homeostatic and inflammatory conditions have
reduced numbers of circulating inflammatory blood mono-
cytes in the peripheral blood compared to CCR2+/+ mice,
while the resident Ly6C− monocyte subset remains unal-
tered [34, 35]. In CX3CR1-GFP transgenic reporter mice
[8], circulating monocytes are distinguished based on their
differential CX3CR1-GFP expression. The inflammatory
monocyte subset is GFPlo while resident-type monocytes
are GFPhi. Inflammatory GFPlo monocytes upregulate
MHC class II and CD11c after migration to the site of
inflammation. Thereafter, they move to the draining
lymph node where they may further differentiate into
DCs [20]. In contrast, the resident (GFPhi) monocytes
have a longer life span and, after adoptive transfer, they
reconstitute tissue macrophage populations and DCs also
under homeostatic conditions [20], while GFPlo cells may
migrate back to the BM without entering the peripheral
tissues in the absence of inflammation [10] (Fig. 1).
Similar to human monocytes, the two main mouse
monocyte subsets can differentiate into DCs in vitro in
the presence of IL-4 and GM-CSF [20].
One of the central questions of monocyte differenti-
ation is the time and site of differentiation into
inflammatory vs. resident monocyte subsets and to
which extent monocytes of one subset may later also
acquire phenotypic and functional properties of the
other subset. In adoptive transfer experiments where
both subsets were introduced in recipient mice under
homeostatic conditions, inflammatory (Ly6C+) mono-
cytes disappeared rapidly from the circulation, while the
resident monocytes (Ly6C−) persisted. The disappearance
of the Ly6C+ inflammatory monocytes was mostly due to
a conversion of the inflammatory subset into the resident
Ly6C− subset. Ly6C+ monocytes shuttled back to the BM,
converted into Ly6C− monocytes, and contributed further
to the generation of mononuclear phagocytes as resident-
type monocytes [10]. A similar downregulation of Ly6C
was also observed in in vitro cultures when Ly6Chi-
expressing cells were differentiated into macrophages [36–
38]. Repopulation studies in mice that were depleted of all
circulating monocytes by treatment with clodronate-
loaded liposomes, revealed in the peripheral blood a
population of Ly6C+ cells already 3–4 days after deple-
tion, while first Ly6C− monocytes only appeared after
more than 1 week after depletion. Together with previous
observations that Ly6C+ monocytes downregulate Ly6C
expression and may convert into Ly6C− monocytes in
vivo, this study suggests that the inflammatory Ly6C+
monocyte subset contains the precursors of the Ly6C−
resident-type monocytes. During this phenotypic and
functional conversion, cells with an intermediate pheno-
type are detected (approximately 5% of the circulating
monocytes), characterized by the intermediate expression
of Ly6C, which may correspond to the CD14+, CD16+,
and CD64+ transitional monocytes found in humans [38].
Ly6Cint monocytes express a broader spectrum of chemo-
kine receptors and may preferentially migrate to draining
lymph nodes due to their expression of CCR7 and CCR8
[39]. The conversion from Ly6C+ to Ly6C− monocytes
was significantly altered in models of acute (L. mono-
cytogenes) and chronic (L. major) infection, resulting in a
significant increase of the immature Ly6C+ monocyte
population [38]. The correlation of a resident vs. an
inflammatory phenotype with a defined functional profile
remains poorly characterized also for mouse monocyte
subsets. Resident (Ly6C−) blood monocytes were de-
scribed as cells with a patrolling behavior that allowed
them to rapidly invade tissues in case of tissue damage or
infection. These Ly6C− cells initiated an early innate
immune response at sites of inflammation, mainly by
producing TNF, and then differentiated into macrophages
[40]. This is in contrast to the inflammatory (Ly6C+)
monocytes, which arrive later at sites of infection and
show a more DC-like phenotype [41].
The limited insight into the biological and functional
properties of distinct monocyte subsets can be attributed
to the absence of specific markers to distinguish the
various differentiation and also activation stages of the
MPS. The phenotypic and functional heterogeneity of
the monocyte/macrophage system may be attributed to
the remarkably dynamic adaption of macrophage subsets
to their microenvironment. This is in part also reflected
by the different macrophage subsets that can be
generated in vitro with distinct sets of cell-derived and
environmental stimuli [21, 22, 42]: Classical activation
can be induced by in vitro culture of macrophages with
IFNγ and LPS. This results in increased antigen presen-
tation, production of proinflammatory cytokines, and an
enhanced microbicidal activity. In vitro activation of
monocytes in the presence of Th2-type cytokines (IL-4
or IL-13) yields the so-called alternatively activated
macrophages characterized by an increased endocytic
activity, cell growth, tissue repair, and parasite killing.
The culture of monocytes/macrophages in the presence of
IL-10 and transforming growth factor-β (TGFβ) is
associated with an anti-inflammatory (or regulatory)
phenotype with increased production of IL-10, TGFβ,
and PGE2. However, it is still unclear whether
corresponding macrophage subsets also exist in vivo and
to which extent the differentiation of macrophage lineages
is predetermined. It appears likely that in vivo macro-
phages are exposed to a broad range of soluble and cell
surface-expressed mediators that have the potential to
activate and differentiate macrophages in a much more
elaborate manner than can be mimicked by an in vitro
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culture and, consequently, may result in a highly versatile
macrophage phenotype.
The intestine as a major reservoir of macrophages
The gastrointestinal tract represents the most complex and
extensive compartment of the immune system. Due to the
sophisticated modifications of the small intestinal mucosa,
including folds, villi, and microvilli, the total intestinal
surface (in humans) amounts up to 300–400 m2 and the
number of colonizing luminal bacteria (up to 1014),
representing approximately 1,000 different species, even
exceeds the number of cells of the human body [43, 44]. A
monolayer consisting of epithelial cells serves as a physical
barrier that restricts the penetration of luminal antigens and
microbial products and helps to retain the commensal
bacteria in the gut lumen. At the same time, the intestinal
lamina propria contains an enormous number of immune
cells with potent effector functions. About 70% of all
lymphocytes are located within the mucosal immune
system, and approximately 10% of all intestinal lamina
propria mononuclear cells are found to be macrophages
[45]. The luminal bacterial density increases from the small
intestine (SI) to the ileum (distal portion of SI) and the large
bowel. Accordingly, intestinal macrophages are most
abundant in the colon with slightly lower frequencies in
the SI. Hence, the mucosa of the small and the large
a Normal colon b Normal ileum
c Ulcerative colitis (UC) d Crohn’s disease (CD)
Fig. 3 Immunostaining for the macrophage-specific cytoplasmic protein
CD68 on human intestinal tissue sections. Under homeostatic conditions
(a, b), most macrophages (brown) are strategically located in the
subepithelial mucosa, while during active flares of IBD (c, d), the tissue
architecture is massively distorted and the numerous macrophages are
dispersed in the affected intestinal segments
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intestine represents the largest reservoir of tissue macro-
phages in humans [45] and mice [46]. Under homeostatic
conditions, most of the intestinal macrophages are located
in the subepithelial mucosa, i.e., at the preferential site of
antigen entry (Fig. 3a, b). At these strategic positions, they
are instrumental for the rapid elimination of gut lumen-
derived bacteria that have breached the epithelial barrier.
The highly efficient phagocytic and bactericidal activity of
intestinal macrophages prevents the dispersal and prolifer-
ation of possibly harmful bacteria. Hence, resident intesti-
nal macrophages exert critical functions for maintaining
local tissue homeostasis including the efficient removal of
apoptotic cells and foreign debris [47]. Despite the
proximity of the large number of intestinal macrophages
to the antigen- and bacteria-rich environment, only minimal
signs of inflammation are observed in the gut [48]. Under
homeostatic conditions, resident intestinal macrophages,
together with regulatory T cells, inhibitory DCs, and
possibly even endothelial cells, produce immunomodulato-
ry cytokines that prevent excessive inflammation [49].
Distinct properties of intestinal lamina propria
macrophages
The local tissue microenvironment substantially affects
the functional and phenotypic differentiation of tissue
macrophages. Hence, during the coevolution of the host
immune system with the intestinal flora, the macrophage
compartment in the intestine developed several func-
tional adaptations to maintain local tissue homeostasis
(Fig. 4). In contrast to their progenitor cells, the resident
monocytes, intestinal macrophages do not serve as
professional antigen-presenting cells (APC) due to their
low, or even absent, cell surface expression of CD40,
CD80, and CD86 [50]. Intestinal macrophages are
deficient in several innate immune recognition mecha-
nisms and activating receptors [51, 52] that make them
refractory to LPS and other microbe-associated molecular
patterns (MAMP), which are present abundantly in the
intestinal microflora. They also lack the Fc receptors for
IgA (CD89) and for IgG (CD16, CD32, and CD64) [52]
and the complement receptors CR3 (CD11b/CD18) and
CR4 (CD11c/CD18), and most intestinal macrophages
also lack the integrin α2β1 (LFA-1 and CD11a/CD18)
[53]. These Fc and complement receptors on phagocytes
usually mediate cellular activation, secretion of proin-
flammatory cytokines (such as TNF, IL-1β, IL-6, IL-8,
and IL-12), and induction of potent adaptive immune
responses [53]. These adaptations, however, do not impair
the phagocytic activity which is exceptionally potent in
intestinal macrophages [53].
Normal intestinal lamina propria macrophages are
generally not only refractory to the induction of proin-
flammatory cytokine production by MAMP (e.g., LPS, or
heat-killed S. aureus, muramyl dipeptides), but also by
cytokines (e.g., TNF, IFNγ), or upon phagocytosis of
necrotic cells [18, 53]. This is in sharp contrast to most
other tissue macrophages and blood monocytes. Intestinal
macrophages also mostly lack the triggering receptor
expressed on myeloid cells-1 (TREM-1), an efficient
amplifier of acute and chronic inflammatory reactions that
is generally expressed on peripheral blood neutrophils and
most monocytes and macrophages of secondary lymphoid
organs [54]. Engagement of TREM-1 on TREM-1-positive
myeloid cells leads to enhanced secretion of proinflamma-
tory mediators (e.g., TNF, IL-1β, MCP-1, IL-6, and IL-8)
by monocytes, upregulates several cell surface molecules
(e.g., CD40, CD86, and CD32) on monocytes, and pro-
longs the survival of TREM-1-positive inflammatory cells
[54, 55].
Such a selective inflammatory anergy of intestinal
macrophages in the presence of avid host defense and
scavenger functions represents an optimized functional
adaptation of these effector cells located in close
proximity to the extraordinary load of mostly commen-
sal bacteria-derived, immunostimulatory molecules in
the gut lumen. These adaptations efficiently contribute
to limiting the dissemination of luminal bacteria to the
local mucosa and are also a prerequisite for the tight
regulation of the immune responses of the adaptive
immune system in the intestinal mucosa. As a further
illustration of such a perfect functional adaptation,
murine colonic macrophages become triggered to pro-
duce large amounts of IL-10 after encountering whole
commensal bacteria [56].
Blood
Monocyte
Intestinal
Macrophage
HLA-DR, CD33, CD13
TGF-βRI, TGF-βRII
CD80, CD86, CD40
CD14, TLR2, TLR4
TREM-1, CD89
CD16, CD32, CD64
CD25, CD123
CCR5, CXCR4
+
+
-
-
-
-
-
-
+
+
+
+
+
+
+
+
Phagocytosis
Killing
Bactericidal activity
Chemotaxis
Co-stimulation
Cytokine production 
+
+
+
-
-
-
+
+
+
+
+
+
Ph
en
ot
yp
e
Fu
nc
tio
n
Mo
M Mo
Mø
ø
Fig. 4 Distinct phenotypic and
functional properties of intesti-
nal macrophages and blood
monocytes. The presence, or
absence, of a particular marker
or functional feature is indicated
as plus sign and minus sign,
respectively. Data are collected
from refs. [50–54, 86, 98, 112–
114] and the authors’ own un-
published results. Mø macro-
phage, Mo monocyte
Semin Immunopathol (2009) 31:171–184 177
Regulation of phenotype and functions of intestinal
macrophages
A variety of intestinal cell types including epithelial cells,
subepithelial myofibroblasts, fibroblasts, lamina propria
lymphocytes, and intraepithelial lymphocytes are all able
to produce soluble factors, particularly, TGFβ and IL-10,
which may affect the phenotypic and functional properties
of intestinal macrophages [57–60]. The importance of
stromal cell-derived factors in shaping the functional
capacities of intestinal macrophages is illustrated by the
effects induced in blood monocytes upon exposure to
intestinal stromal cell-conditioned media. This treatment
reduced the expression of several innate response receptors,
induced inflammatory anergy, and increased their phago-
cytic activity, similar to normal intestinal macrophages.
These effects were efficiently blocked by anti-TGFβ
antibodies, thus confirming the central role for TGFβ in
this process [53]. IL-10, another relevant immunomodula-
tory cytokine produced under physiological conditions in
the intestinal lamina propria, might also influence the
functional properties of intestinal macrophages either by
directly dampening monocyte/macrophage functions or
indirectly by upregulating TGFβ production in distinct cell
types, including immature DCs and macrophages [61–63].
Intriguingly, monocytes cultured in the presence of recom-
binant TGFβ alone or together with IL-10 did not gain an
intestinal macrophages-like phenotype such as absence of
CD14, whereas IL-10 and TGFβ synergistically down-
regulate CD89 and TREM-1 surface expression on blood
monocytes and prevented the upregulation of these markers
by proinflammatory stimuli such as LPS or TNF [54]. This
indicates that, in addition to IL-10 and TGFβ, other
intestinal mucosa-derived factors and cognate cell–cell
interactions may be required for the full differentiation of
recruited monocytes into resident intestinal macrophages.
Indications for the additional requirement of cognate
interactions between macrophages and intestinal epithelial
cells for the complete differentiation into resident intestinal
tissue macrophages was indeed obtained in cocultures of
monocytes with multicellular spheroids of intestinal epithe-
lial cells. In these in vitro cocultures, the monocytes
acquired an intestinal macrophage-like phenotype, charac-
terized by reduced CD14, CD16, CD11b, and CD11c
expression and reduced LPS-stimulated IL-1β mRNA
expression [64]. This effect, however, was not seen in
transwell coculture of monocytes with the same epithelial
cells or epithelial cell-conditioned medium and, hence, is
likely to require direct cell–cell contacts between macro-
phages and intestinal epithelial cells [64]. Intestinal
lamina propria macrophages are separated from the epithe-
lial cells by the basement membrane [65]. However,
subepithelial macrophages may directly interact with
intestinal epithelial cells by sending cell protrusions
through pores present in the basement membrane [66].
Components of the basement membrane and extracellular
matrix were indeed also found to affect macrophage
differentiation [67].
The efficient phagocytosis mediated by intestinal lamina
propria macrophages should not only be viewed as a mere
clearing of potentially harmful agents and dying cells, but
may also contribute actively to the establishment of a local
immunosuppressive milieu. Phagocytosis of apoptotic cells
may induce in macrophages the secretion of immunosup-
pressive cytokines such as IL-10, whereas the secretion of
proinflammatory cytokines such as TNF, IL-12, and IL-1β
is significantly reduced [68–70]. Hence, phagocytosis of
apoptotic cells may actively alter the functional behavior of
intestinal macrophages.
Site-specific differences in the cellular composition
of the intestinal mucosa
The intestinal immune system is the largest and most
complex part of the immune system and each compartment
of the intestine, from the duodenum to the ileum and the
cecum to the rectum, displays distinct regional special-
izations that may directly affect the functional properties of
the local resident immune cells. Most of the intestinal
macrophages accumulate beneath the epithelium covering
the luminal surface of the lamina propria (Fig. 3a, b). This
characteristic distribution pattern is commonly seen at all
intestinal sites, including gastric, duodenal, ileal, colonic,
and even fetal gastrointestinal mucosa [71]. When com-
pared to macrophages in the deeper lamina propria,
subepithelial macrophages display an abundant cytoplasm,
containing prominent phagocytosed vesicles or fragments,
reminiscent of their high phagocytic activity and efficient
elimination of dying cells and foreign particles [72].
Unfortunately, at present, no specific markers are described
to further differentiate resident macrophages of the normal
intestine in humans and in mice. In particular, in contrast to
DC subsets, no differences in the chemokine receptor
expression patterns by intestinal macrophages from distinct
anatomical sites of the intestinal tract were reported so far.
Macrophage subsets in the normal and inflamed
intestinal mucosa
The intestinal epithelium represents a physical barrier that
is far from being tight and, thus, luminal bacteria may
breach the epithelial barrier to get access to the subepithe-
lial lamina propria. These invading commensal bacteria are
rapidly phagocytosed by the lamina propria macrophages,
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which are strategically located underneath the epithelium.
This is most obvious in the large intestine where the
concentration of luminal bacteria is several orders of
magnitude higher than in the SI and where highest
frequencies of subepithelial macrophages are seen
(Fig. 3a, b). The importance of the functional adaptations
of the local intestinal immune system to its unique
environment is best illustrated during failure of these
mechanisms, e.g., during the development of chronic
intestinal inflammation, either in patients with celiac
disease, inflammatory bowel diseases (IBD), or in various
mouse strains deficient for genes involved in the control of
immune responses such as IL-10 and TGFβ [73–76].
Deregulated immune response(s) against an otherwise
harmless luminal microflora in susceptible individuals is
now generally recognized as a key factor in the pathogen-
esis of IBD.
Celiac disease
Celiac disease, or celiac sprue, is a malabsorption
syndrome which is initiated in genetically predisposed
persons by the ingestion of gluten, a major protein of
wheat and related cereals. The disease is triggered by
exposure to gliadin peptides, which are derived from
protease-digested gluten and are transported across the
intestinal epithelial barrier to the lamina propria where
they are deamidated by the enzyme tissue transglutami-
nase (tTG). These deamidated, gliadin-derived neoantigens
are preferentially presented by HLA-DQ2 or HLA-DQ8
molecules to pathogenic CD4 T cells in the lamina propria
[77]. Histologically, the affected small intestinal mucosa in
florid celiac disease reveals a hyperplasia of the crypt cells,
a hypercellularity of the lamina propria with locally
increased numbers of CD4 T cells and plasma cells,
together with an atrophy of the villi, leading to a complete
flattening of the mucosa. These morphological changes are
generally reversible during a gluten-free diet. Intestinal
intraepithelial lymphocytes are typically increased in florid
celiac disease and particularly TCRγδ T cells are overrep-
resented in the affected small intestinal epithelium. The
interaction of the activating receptor NKG2D on a subset of
small intestinal TCRγδ T cells with the cognate NKG2D
ligand on enterocytes, i.e., the class Ib molecules MICA/B,
can induce cytotoxic effector functions in subsets of
TCRγδ T cells and CD8 TCRαβ T cells, thus, contributing
to the characteristic villous atrophy in patients with florid
celiac disease [78, 79]. In addition to these lymphocyte-
mediated effects, a disease-exacerbating role has been also
ascribed to macrophages in response to the enhanced
presence of gliadin in the small intestinal mucosa:
Gliadin-derived peptides reportedly directly stimulated
peritoneal macrophages for an enhanced secretion of
cytokines including TNF and the monocyte recruiting
chemokine CCL5 [80]. In an in vitro system, gliadin also
enhanced the epithelial permeability and a MyD88-
dependent increased synthesis of IL-12 and TNF in primary
mouse macrophages [81].
Inflammatory bowel diseases
IBD cover two major clinical entities, i.e., ulcerative colitis
(UC) and Crohn’s disease (CD). In UC, the inflammatory
process is restricted to the mucosa of the large bowel and
only in the most active stages of the disease may lead to
ulcerations. Excessive inflammation in CD may involve
any part of the gastrointestinal tract with the SI and/or the
colon being most often affected. In CD, all layers may be
involved by the inflammatory reaction and fissures and
fistula formation are a severe complication of active
disease. In CD, segments of macroscopically normal bowel
may be present between affected bowel segments (“skip
lesions”). The breakdown of oral tolerance, i.e., loss of
attenuated T cell responses against the indigenous flora,
may initiate IBD in genetically susceptible individuals and
can result from alteration(s) in signaling pathways of PRRs,
as it is likely the case for mutations in the NOD2/CARD15
locus that represents a susceptibility locus for CD [82–84].
Therefore, deregulated MAMP signaling and the resulting
defects in APCs function or in APC–T cell interactions may
lead to deregulated T cell responses. Hence, aberrant
activation and functions of intestinal macrophages are also
likely to contribute to chronic intestinal inflammation.
In the inflamed intestinal mucosa of patients with active
IBD, the numbers of macrophages are increased (Fig. 3c,
d). Some of these macrophages display a different
phenotypic and functional profile than under physiological
conditions. In contrast to the characteristic anti-
inflammatory phenotypic and functional profile of normal
intestinal lamina propria macrophages, at sites of mucosal
inflammation, macrophages express relevant levels of T cell
costimulatory molecules such as CD40, CD80, and CD86
[50]. Furthermore, subsets of intestinal macrophages ex-
press PRRs such as TLR2 and TLR4 at the site of intestinal
inflammation. These inflammatory macrophages often
coexpress CD14, CD89, and TREM-1 [18, 51, 85–87]. In
these inflammatory conditions, the close proximity of
subepithelial macrophages to the intestinal flora thus results
in a constant, excessive activation of the mucosal innate
immune system and monocytes recruited during inflamma-
tory conditions likely fail to acquire the tightly regulated
and adapted intestinal macrophage phenotype. Consequent-
ly, they may react to luminal antigens, function as potent
effector cells, exert high antigen-presenting capability, and
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become potent producers of proinflammatory cytokine [51].
Since both costimulatory molecules and “danger signals”
are present, these macrophages trigger the adaptive immune
system to react against luminal antigens. Under inflamma-
tory conditions, the epithelial barrier function is usually
disturbed and, as a result, the influx of luminal microbes
and microbial products to the lamina propria is increased.
This further enhances the activation and recruitment of
additional inflammatory cells to sustain the inflammatory
process. The DAP-12-associated activating receptor
TREM-1 triggers the synthesis and secretion of proinflam-
matory cytokines, and consequently, the local tissue
destruction. In the affected areas of patients with active
UC or CD, TREM-1-expressing macrophages are signifi-
cantly increased when compared to normal intestinal
tissues. Engagement of TREM-1 on positive macrophages
in patients with active IBD leads to a significant, several-
fold increased secretion of TNF and other proinflammatory
mediators such as IL-1β, MCP-1, IL-6, and IL-8 [87].
Hence, deregulated macrophage functions at distinct levels
likely contribute to the development and perpetuation of
intestinal inflammation characteristically seen in patients
with IBD [88].
The relevance of appropriate macrophage regulation for
maintaining local tissue homeostasis in the gut has been
also nicely demonstrated in mouse models. As an example,
selective disruption of Stat3 signaling in macrophages leads
to severely impaired production of IL-10 and consequently
leads to the spontaneous development of colitis [89].
Similarly, IL-10−/− mice spontaneously develop colitis as
a consequence of the preferential macrophage differentia-
tion into proinflammatory subsets that produce large
amounts of IL-12 and IL-23. Remarkably, the depletion of
macrophages in these IL-10−/− mice prevents the develop-
ment of colitis [56].
Several observations in patients provided additional,
circumstantial evidence for a central participation of macro-
phages in the pathogenesis of IBD. As an example,
recurrent infections with pathogens that directly target the
macrophages (e.g. M. paratuberculosis, M. avium, or
paramyxoviruses) were repeatedly reported in patients with
IBD. Therefore, deregulated or aberrant responses of
macrophages in patients with IBD to these intracellular
pathogens may be involved in the disease process. This
notion is further supported by the molecular characteriza-
tion of the first IBD susceptibility locus (ibd1), i.e., NOD2/
CARD15, which is also expressed in monocytes and
macrophages [82, 83] and reacts with the bacterial
component muramyl dipeptide [90, 91]. The mutant form
of NOD2 (3020insC), associated with CD, does not appear
to respond to muramyl dipeptide-mediated stimulation [91–
94]. At present, it is still controversial whether NOD2 is a
positive, or negative, regulator of TLR2-mediated
responses that may be impaired in the presence of the
mutated NOD2 [95–97]. Remarkably, another recently
characterized IBD susceptibility locus is the receptor for
IL-23, a proinflammatory cytokine produced predomi-
nantly by cells of the monocyte/macrophage lineage.
Intriguingly, in patients with active CD, but not in
patients with UC, intestinal macrophages produced
significantly more IL-23 than intestinal macrophages
from noninflamed mucosa. The enhanced production of
IL-23 by intestinal macrophages from patients with CD
upon in vitro culture was dependent on local IFNγ
secretion and was further increased in the presence of
commensal bacteria (E. coli, E. faecalis). In contrast to the
production of IL-23, which was induced only in lamina
propria macrophages from CD patients, mRNA expression
and production of IL-6 was increased in lamina propria
macrophages from both UC and CD patients when
compared with macrophages obtained from noninflamed
intestinal lamina propria of control patients [98].
The importance of macrophages in the pathogenesis of
IBD is supported by reports identifying macrophages as the
main source of TNF during the pathogenesis of IBD and
the beneficial effects of anti-TNF treatments in patients
with CD. The striking effects of this TNF-targeted therapy
may in IBD also be attributed to the cell-depleting effect of
some of these therapies, including the removal of TNF-
expressing monocytes/macrophages [99]. TNF produced by
nonlymphoid cells (mostly macrophages) is essential for
colitis in an adoptive T cell model of colitis induction in
lymphopenic recipients. Intriguingly, in this mouse model,
TNF production by the transferred CD4 T cells was not
required, nor sufficient, for disease induction when non-
lymphoid cells, i.e., mostly macrophages, produced TNF in
the affected intestinal mucosa [100].
Conclusions
Until recently, the research on the etiopathogenetic role of
intestinal immunopathological disorders such as celiac
disease and IBD mostly focused on effector mechanisms
of the adaptive immune system such as pathogenic and
regulatory T cell subsets, whereas the innate immune
system had received relatively little attention. However,
the past few years witnessed several important advances
that indicated a central role for cells of the innate immune
system in the pathogenesis of these disorders. The
relevance of intestinal macrophages in the pathogenesis
of IBD is highlighted by their functions as gatekeepers,
driving adaptive immune responses to either tolerance
induction or initiation of inflammatory reactions. Elucida-
tion of the detailed mechanisms of how local macrophages
and/or blood monocytes functionally differentiate and
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participate in the pathogenesis of various inflammatory
disorders may allow designing specific strategies to target
the induction of deregulated adaptive immune responses
and excessive inflammation. Detailed knowledge about
monocytes/macrophage lineage relationships, differential
homing capacities, and the plasticity of these cell subsets
is crucial to design rational strategies to interfere with
their involvement in excessive immunopathological reac-
tions, including chronic inflammatory disorders of the
gastrointestinal tract.
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